Gene Centric Therapeutics
Biotechnology, 280 S Mangum St, Research Triangle Park, North Carolina, 27701, United States, 11-50 Employees
Phone Number: 91********
Who is GENECENTRIC THERAPEUTICS
GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perous laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine. Gene...
Read More
-
Headquarters: 280 S Mangum St, Research Triangle Park, North Carolina, 27701, United States
-
Date Founded: 2011
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Michael Milburn
Email
Phone
Industry: Biotechnology
SIC Code: 3829
|
NAICS Code: 621512 |
Show More
Does something look wrong? Fix it. | View contact records from GENECENTRIC THERAPEUTICS
GeneCentric Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding GeneCentric Therapeutics
Answer: GeneCentric Therapeutics's headquarters are located at 280 S Mangum St, Research Triangle Park, North Carolina, 27701, United States
Answer: GeneCentric Therapeutics's phone number is 91********
Answer: GeneCentric Therapeutics's official website is https://genecentric.com
Answer: GeneCentric Therapeutics's revenue is $10 Million to $25 Million
Answer: GeneCentric Therapeutics's SIC: 3829
Answer: GeneCentric Therapeutics's NAICS: 621512
Answer: GeneCentric Therapeutics has 11-50 employees
Answer: GeneCentric Therapeutics is in Biotechnology
Answer: GeneCentric Therapeutics contact info: Phone number: 91******** Website: https://genecentric.com
Answer: GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perous laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine. GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSPTM) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSPTM was licensed to and independently developed by Laboratory Corporation of America Holdings (LabCorp) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentrics second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month